FDA Accepts Supplemental New Drug Application (sNDA) for TEFLARO(R) (ceftaroline fosamil)
Application Seeks to Expand Label with New Data on Pediatric Patients 2 Months of Age and Older with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP)
DUBLIN, Feb. 16, 2016 -- (Healthcare Sale... Biopharmaceuticals, FDAAllergan, TEFLARO, ceftaroline, MRSA
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Bacterial Pneumonia | Infectious Diseases | MRSA | New Drug Applications | Pediatrics | Pharmaceuticals | Pneumonia | Skin | Superbugs